Cadence Pharmaceuticals Reports First Quarter 2009 Financi... (. Eastern Time) and interested investors...)

Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results

Date:5/7/2009

. Eastern Time) and interested investors may participate in the conference call by dialing 877-856-1961 (domestic) or 719-325-4792 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "expects," "anticipates," "plans," "will," and "assuming," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding: Cadence's belief that it has completed the clinical development program for Acetavance, the timeframe in which it expects to file a New Drug Application, or NDA, for Acetavance, the anticipated cost savings from the discontinuation of the company's Omigard development program, and the adequacy of Cadence's existing financial resources to enable it to successfully launch Acetavance. The inclusion of forward-looking statements should not be regarded as a representation
'/>"/>

0

GOOD

Post Your Comments:

Cadence Pharmaceuticals Reports First Quarter 2009 Financi...(. Eastern Time) and interested investors...)